In 2024 the Future Healthcare 100 conference, jointly organised by VB100, VCBeat, the Eggshell Research Institute and VCBeat Orange, was upgraded into the eighth VBEF Future Healthcare Ecosystem Expo, which opened in Beijing on 7 May. The 2024 Future Healthcare 100 results were published on 9 May.
After review, Westlake Pharmaceuticals was named to the “2024 Future Healthcare 100 — China Innovative Medicines and Biologics Top 100”. (The full list appears at the end of this article.)
The Future Healthcare 100 is China’s first ranking of innovative healthcare companies that are not yet listed. Created in 2015, it aims to identify the innovators that genuinely represent the future of healthcare and the core strength of China’s healthcare industry.
The main ranking is based on the VB100 valuation model. Through company applications, review by the VB100 panel, cross-review by supporting institutions and final assessment by an expert committee, it selects the top 100 by valuation in four fields — innovative devices and intelligent manufacturing, innovative medicines and biologics, healthcare and health innovation services, and healthcare industry chain services. Beyond valuation, reviewers also assess growth and annual performance across four primary indicators (human resources, knowledge resources, key partner resources and market performance) and 17 secondary indicators.
After eight years the list has become an investment bellwether for healthcare and a reference for later-stage financing.
Westlake Pharmaceuticals is dedicated to original medicines for major human diseases. Since its founding in 2020 it has put patient need first and kept exploring the technology frontier, focusing on small-molecule targeted therapies in antiviral and oncology research.
Inclusion affirms what the company has achieved and what it is expected to become. Westlake Pharmaceuticals will keep increasing R&D investment and deepening collaboration with academia and industry.
The main ranking covers unlisted companies in healthcare. Its four fields include innovative medicines and biologics, whose full top 100 list follows.
